Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 32,80 € (+27.233,33%). La mediana è 32,80 € (+27.233,33%).
| Acquista |
4 |
| Mantieni |
1 |
| Vendi |
0 |
Notizie Vai al feed delle notizie
BiomX acquires 10% of M.E.A. Testing Systems and secures option to buy majority
BiomX purchases 324,573 shares (10% diluted) of M.E.A. Testing Systems for $50,000 and 1,300,000 restricted common shares, and receives an exclusive option until June 30, 2028 to acquire the remaining approximately 78.9% at a price of two times net revenue or four times EBITDA for fiscal year 2027. Closing is contingent on approval of an NYSE American listing application and the execution of a license agreement that grants BiomX exclusive worldwide rights to MEA technologies, including drone testing solutions. The transaction takes place despite strained liquidity at BiomX (debt-funded free cash flow of -$23m; financial health score 1.45) and is accompanied by the appointment of Roy Timor-Rousso as chief business officer to strengthen focus on defense and security technologies. » Altro su de.investing.com
BiomX completes acquisition of AI security software provider Zorronet
BiomX has completed the full takeover of Zorronet from Water.io, expanding its portfolio with AI-driven command-and-control software that links video analytics, drones, sensors and IoT into an operational picture. Zorronet holds contracts with the Israel Defense Forces and Israel Railways and serves customers such as Elbit Systems, addressing defense, security and rescue segments. BiomX has a market capitalization of around USD 20 million and a current ratio of 2.7, but faces challenges from rapid cash burn despite a high gross margin. » Altro su de.investing.com
BiomX reports quarterly EPS of -21.39 USD and reduces annual loss
BiomX released figures for the quarter ended 31 December 2025 with earnings per share (EPS) of -21.39 USD versus -21.85 USD a year earlier. For the fiscal year the company reported a loss per share of -22.19 USD after -27.93 USD in the prior year. » Altro su finanzen.net
Dati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 290,9K | - |
| Utile lordo | 84,99K | 134,31% |
| Utile netto | -3,31 Mln | 35,47% |
| EBITDA | -3,34 Mln | 31,02% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 1,21 Mln € |
Numero di azioni | 10,15 Mln |
Massimo/minimo a 52 settimane | 10,61 € - 0,10 € |
| Dividendi | No |
Beta | 1,37 |
Rapporto P/E | -0,01 |
Rapporto PEG | 0,00 |
Rapporto P/B | 0,13 |
Rapporto P/S | 4,23 |
Profilo aziendale
| Nome | BIOMX INC. NEW Aktie |
| CEO | Michael Oster |
| Dipendenti | 20 |
Scopri gli asset
Gli azionisti di BIOMX INC. NEW Aktie investono anche nei seguenti asset




